Drug Developers Actively Improving Efficiency of Clinical Trials, According to Tufts Center for the Study of Drug Development
April 26, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Apr 26, 2011) - Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with...
BancVue Named One of the 10 Most Innovative Companies in Finance by Fast Company
March 21, 2011 12:19 ET
|
BancVue
AUSTIN, TX--(Marketwire - March 21, 2011) - BancVue (www.BancVue.com), the leading provider of innovative products, dynamic marketing, and data-driven consulting solutions to over 1,300 community...
U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily, According to Tufts Center for the Study of Drug Development
March 08, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 8, 2011) - New or modified indication approvals for existing prescription drugs have steadily increased in the United States since the late 1990s, according to an...
Translational Science Expected to Play a Growing Role in Creating New Drugs, According to Tufts Center for the Study of Drug Development
January 27, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2011) - To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to...
U.S. Healthcare Stakeholders Uncertain About Benefits of Risk Evaluation Program, According to Tufts Center for the Study of Drug Development
January 12, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 12, 2011) - Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about...
Drug Developers Are Aggressively Changing the Way They Do R&D, According to Tufts Center for the Study of Drug Development
January 05, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 5, 2011) - With dozens of prescription drugs due to lose their patent protection in the next few years, and few likely blockbusters in company pipelines to replace...
Personalized Medicines Are Shaping the Way R&D Is Done, According to Tufts Center for the Study of Drug Development
November 16, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 16, 2010) - Personalized medicine development, occupying a growing role in the clinical pipelines of drug developers, is leading companies to change their R&D...
Pharma and Biotech Firms Are Rethinking Their Approach to Outsourcing, According to Tufts Center for the Study of Drug Development
October 26, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 26, 2010) - The current business climate is challenging pharmaceutical and biotech companies to rethink their approach to outsourcing and how best to build...
Approval Success Rates Higher for Smaller Firms Among Top 50 Pharmaceutical Companies, According to Tufts Center for the Study of Drug Development
September 09, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2010) - The top 10 pharmaceutical companies out of the world's top 50 have lower estimated overall clinical approval success rates than do smaller firms in that...
Portfolio Management Is Key to Improved Drug Development Productivity, According to Tufts Center for the Study of Drug Development
August 11, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - August 11, 2010) - Drug developers need to change the way they allocate resources for new product development, lifecycle management, and business development and...